These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 31097093)

  • 1. Epidermal growth factor receptor-targeted immunomagnetic liposomes for circulating tumor cell enumeration in non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors.
    Cui S; Ni Y; Zhao Y; Li Z; Xiong L; Liu J; Liang X; Jiang L
    Lung Cancer; 2019 Jun; 132():45-53. PubMed ID: 31097093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients Treated With First-Line EGFR Tyrosine Kinase Inhibitors.
    Jiang T; Zhao J; Zhao C; Li X; Shen J; Zhou J; Ren S; Su C; Zhou C; O'Brien M
    Clin Lung Cancer; 2019 Mar; 20(2):124-133.e2. PubMed ID: 30587399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients.
    Yang B; Qin A; Zhang K; Ren H; Liu S; Liu X; Pan X; Yu G
    Oncol Res; 2017 Nov; 25(9):1601-1606. PubMed ID: 28474575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study.
    Auliac JB; Fournier C; Audigier Valette C; Perol M; Bizieux A; Vinas F; Decroisette Phan van Ho C; Bota Ouchlif S; Corre R; Le Garff G; Fournel P; Baize N; Lamy R; Vergnenegre A; Arpin D; Marin B; Chouaid C; Gervais R
    Target Oncol; 2016 Apr; 11(2):167-74. PubMed ID: 26315967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of tissue re-biopsy in non-small cell lung cancers resistant to previous epidermal growth factor receptor tyrosine kinase inhibitor therapies.
    Uozu S; Imaizumi K; Yamaguchi T; Goto Y; Kawada K; Minezawa T; Okamura T; Akao K; Hayashi M; Isogai S; Okazawa M; Hashimoto N; Hasegawa Y
    BMC Pulm Med; 2017 Dec; 17(1):175. PubMed ID: 29212495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression.
    Nishino M; Dahlberg SE; Cardarella S; Jackman DM; Rabin MS; Ramaiya NH; Hatabu H; Jänne PA; Johnson BE
    Cancer; 2013 Nov; 119(21):3761-8. PubMed ID: 23922022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
    Yoshida T; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y; Goto K
    Lung Cancer; 2015 Dec; 90(3):477-83. PubMed ID: 26604031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer.
    Hsu CL; Tsai TH; Huang CK; Yang CY; Liao WY; Ho CC; Ruan SY; Chen KY; Shih JY; Yang PC
    Lung Cancer; 2021 Jun; 156():50-58. PubMed ID: 33894494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
    Chen Q; Quan Q; Ding L; Hong X; Zhou N; Liang Y; Wu H
    Oncotarget; 2015 Sep; 6(28):24904-11. PubMed ID: 26172562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor cells predict prognosis following secondline AZD 9291 treatment in EGFR-T790M mutant non-small cell lung cancer patients.
    Yang B; Zheng D; Zeng Υ; Qin A; Gao J; Yu G
    J BUON; 2018; 23(4):1077-1081. PubMed ID: 30358214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
    Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].
    Li JM; Hu J; Bai CX; Zhang Y; Xu XB; Wang XD; Ding N
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):778-782. PubMed ID: 30347549
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
    Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
    Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Traditional Chinese Medicine Prolongs Progression-Free Survival and Enhances Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Treated Non-Small-Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations.
    Tang M; Wang S; Zhao B; Wang W; Zhu Y; Hu L; Zhang X; Xiong S
    Med Sci Monit; 2019 Nov; 25():8430-8437. PubMed ID: 31704907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients.
    Wu TH; Hsiue EH; Lee JH; Lin CC; Liao WY; Ho CC; Shih JY; Yu CJ; Yang JC
    Clin Lung Cancer; 2018 May; 19(3):e361-e372. PubMed ID: 29477365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
    Fan Y; Huang ZY; Yu HF; Luo LH
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of IMMS Containing Multi-site Liposomes for Dynamic Monitoring of Blood CTC in Patients with Osimertinib-resistant Non-small-cell Lung Cancer and its Mechanism.
    Chen X; Luo L; Lu Y; Qiu Y; Liang J; Chen Y; Ning Y; Li B
    Anticancer Agents Med Chem; 2023; 23(6):676-686. PubMed ID: 36345240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
    Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS
    JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.